Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
Diabetes Care, 2024 - diabetesjournals.org
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - diabetesjournals.org
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
«Алгоритмы специализированной медицинской помощи больным сахарным диабетом» Под редакцией ИИ Дедова, МВ Шестаковой, АЮ Майорова 9-й …
ИИ Дедов, МВ Шестакова, АЮ Майоров… - Сахарный …, 2019 - dia-endojournals.ru
Данное издание содержит девятый актуализированный выпуск (дополненный)
клинических рекомендаций по стандартизации и оптимизации оказания медицинской …
клинических рекомендаций по стандартизации и оптимизации оказания медицинской …
Сахарный диабет 2 типа у взрослых
ИИ Дедов, МВ Шестакова, АЮ Майоров… - Сахарный …, 2020 - dia-endojournals.ru
1.1 ОПРЕДЕЛЕНИЕ ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ (ГРУППЫ ЗАБОЛЕВАНИЙ ИЛИ
СОСТОЯНИЙ) 7 1.2 ЭТИОЛОГИЯ И ПАТОГЕНЕЗ ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ …
СОСТОЯНИЙ) 7 1.2 ЭТИОЛОГИЯ И ПАТОГЕНЕЗ ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ …
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …
American Association of Clinical Endocrinology clinical practice guideline: develo** a diabetes mellitus comprehensive care plan—2022 update
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
Kidney fibrosis: from mechanisms to therapeutic medicines
R Huang, P Fu, L Ma - Signal transduction and targeted therapy, 2023 - nature.com
Chronic kidney disease (CKD) is estimated to affect 10–14% of global population. Kidney
fibrosis, characterized by excessive extracellular matrix deposition leading to scarring, is a …
fibrosis, characterized by excessive extracellular matrix deposition leading to scarring, is a …
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 …
Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …